The outcome showed that high TRPV1 expression was associated with better 3-year or 5-year cumulative survival time in the CD8+ T cell, CD4+ T cell and macrophage subsets of ccRCC (Figure S4). This evidence concerns the gene CD4 and nonpapillary renal cell carcinoma.